Spots Global Cancer Trial Database for Pharmacokinetic, Safety and Tolerability Study of SPARC1028
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Official Title:
Study ID: NCT01305512
Conditions
Solid Tumor in Advanced Stage
Interventions
SPARC1028
Study Description
Brief Summary: Evaluation of pharmacokinetic profile of SPARC1028
Detailed Description: This is a phase I study of SPARC1028 and recommend phase II dose of SPARC1028 administered once a week for 3 weeks, followed by 1 week of rest.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
SPARC Site 1, Buffalo, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
